Chinese Medical Journal (Dec 2021)

Low-level viremia in nucleoside analog-treated chronic hepatitis B patients

  • Qian Zhang,
  • Da-Chuan Cai,
  • Peng Hu,
  • Hong Ren,
  • Peng Lyu

DOI
https://doi.org/10.1097/CM9.0000000000001793
Journal volume & issue
Vol. 134, no. 23
pp. 2810 – 2817

Abstract

Read online

Abstract. Low-level viremia (LLV) was defined as persistent or intermittent episodes of detectable hepatitis B virus (HBV) DNA (<2000 IU/mL, detection limit of 10 IU/mL) after 48 weeks of antiviral treatment. Effective antiviral therapies for chronic hepatitis B (CHB) patients, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), have been shown to inhibit the replication of HBV DNA and prevent liver-related complications. However, even with long-term antiviral therapy, there are still a number of patients with persistent or intermittent LLV. At present, the research on LLV to address whether adversely affect the clinical outcome is limited, and the follow-up treatment for these patients is open to question. At the same time, the mechanism of LLV is not clear. In this review, we summarize the incidence of LLV, the association between LLV and long-term outcomes, possible mechanisms, and management strategies in these patient populations.